XML 105 R92.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION - Segment Reporting Information by Segment (Details)
$ in Thousands
 12 Months Ended
Mar. 29, 2025
USD ($)
unit
Mar. 30, 2024
USD ($)
Apr. 01, 2023
USD ($)
Segment Reporting Information [Line Items]      
Number of reportable segments | unit 3    
Net revenues $ 1,360,824 $ 1,309,055 $ 1,168,660
Significant segment expenses and operating performance      
Cost of goods sold 611,866 617,507 553,563
Selling, general and administrative 436,789 431,780 376,675
Research and development 62,722 54,435 50,131
Operating income 221,817 164,883 156,033
Amortization of acquired intangible assets 48,261 32,031 32,640
Interest and other expense, net (9,746) (13,018) (14,630)
Income before provision for income taxes 212,071 151,865 141,403
Total net revenues 1,360,824 1,309,055 1,168,660
Depreciation and amortization 115,586 97,215 93,307
Total long-lived assets 284,052 311,362  
Plasma      
Segment Reporting Information [Line Items]      
Net revenues 535,431 569,535 499,916
Significant segment expenses and operating performance      
Depreciation and amortization 48,264 45,712 41,612
Total long-lived assets 189,833 211,121  
Plasma | Plasma      
Significant segment expenses and operating performance      
Total net revenues 535,431 569,535 499,916
Blood Center      
Segment Reporting Information [Line Items]      
Net revenues 261,124 283,231 287,034
Significant segment expenses and operating performance      
Depreciation and amortization 10,077 13,391 13,927
Total long-lived assets 40,337 54,262  
Blood Center | Blood Center      
Significant segment expenses and operating performance      
Total net revenues 261,124 283,231 287,034
Hospital      
Segment Reporting Information [Line Items]      
Net revenues 564,269 456,289 381,710
Significant segment expenses and operating performance      
Depreciation and amortization 57,245 38,112 37,768
Total long-lived assets 53,882 45,979  
Hospital | Hospital      
Significant segment expenses and operating performance      
Total net revenues 564,269 456,289 381,710
Apheresis | Blood Center      
Significant segment expenses and operating performance      
Total net revenues 213,134 211,173 207,618
Whole Blood | Blood Center      
Significant segment expenses and operating performance      
Total net revenues 47,990 72,058 79,416
Interventional Technologies | Hospital      
Significant segment expenses and operating performance      
Total net revenues 255,019 174,285 126,717
Blood Management Technologies | Hospital      
Significant segment expenses and operating performance      
Total net revenues 309,250 282,004 254,993
Operating Segments [Member] | Plasma      
Significant segment expenses and operating performance      
Cost of goods sold 237,050 264,042 254,474
Selling, general and administrative 98,418 109,729 106,006
Research and development 15,453 13,797 14,690
Operating income 184,510 181,967 124,746
Operating Segments [Member] | Blood Center      
Significant segment expenses and operating performance      
Cost of goods sold 142,512 165,564 144,364
Selling, general and administrative 60,023 67,339 74,024
Research and development 5,770 7,956 4,374
Operating income 52,819 42,372 64,272
Operating Segments [Member] | Hospital      
Significant segment expenses and operating performance      
Cost of goods sold 199,499 167,172 147,831
Selling, general and administrative 241,760 209,680 181,368
Research and development 34,035 27,239 23,096
Operating income 88,975 52,198 29,415
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]      
Significant segment expenses and operating performance      
Operating income 221,817 164,883 156,033
Amortization of acquired intangible assets 63,217 35,378 32,640
Acquisition, integration and divestiture related costs (22,904) (11,249) 411
Restructuring and restructuring related costs 21,158 23,588 11,549
Digital transformation costs 20,273 15,667 4,536
Contingent Consideration 23,022 0 0
Other $ 43 $ (25,772) $ (14,086)